Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|ALTE1631||COG||A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia||Pediatric CIRB||Available to Open|
|AEWS0621||COG||Phase II Trial of Intermediate-Dose Cytarabine to Modulate EWS/FLI for Children and Young Adults with Recurrent or Refractory Ewing Sarcoma||Pediatric CIRB||Completed|
|ADVL1615||COG||A Phase 1 Study of Pevonedistat (MLN4924, IND # 136078), A NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors||Pediatric CIRB||Available to Open|
|ALTE1621||COG||Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial||Pediatric CIRB||Available to Open|
|ADVL0221||COG||A Phase II Study of Trabectedin (ET-743; Yondelis) in Children with Recurrent Rhabdomyosarcoma; Ewing Sarcoma; or Nonrhabdomyosarcomatous Soft Tissue Sarcomas||Pediatric CIRB||Completed|
|PEPN1812||A Phase 1 Trial of the CD123 X CD3 Dual Affinity Re-Targeting Antibody Flotetuzumab (NSC#808294, IND #145986) in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia||Pediatric CIRB||Available to Open|
|ACCL1032||COG||A Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Cisplatin: A Groupwide Phase III Study||Pediatric CIRB||Completed|
|AHOD1331||COG||A Randomized Phase III Study of Brentuximab Vedotin (SGN-35; IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents: A Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|AREN0533||COG||Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors: A Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|AALL07P1||COG||A Phase II Pilot Trial of Bortezomib (PS-341; Velcade; IND# 58;443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)||Pediatric CIRB||Completed|